Form 4: Catalyst Pharmaceuticals Director Denkhaus Reports Stock Unit Vesting

Director Donald A. Denkhaus reports the vesting of restricted stock units into Catalyst Pharmaceuticals common stock.

Summary

• On December 27, 2024, Donald A. Denkhaus, a director of Catalyst Pharmaceuticals, Inc., had 1,333 restricted stock units vest.
• These units converted into 1,333 shares of common stock.
• Following the transaction, Denkhaus directly owns 441,079 shares of Catalyst Pharmaceuticals common stock and 212,274 restricted stock units.
• The restricted stock units vest in three equal tranches annually on December 27, 2023, December 27, 2024, and December 27, 2025.
• Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock unit vesting, and has a neutral sentiment.

Positives

• The vesting of restricted stock units indicates a continued alignment of the director's interests with those of the shareholders.

Future Outlook

The report indicates the final tranche of restricted stock units will vest on December 27, 2025.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The vesting of restricted stock units may have a minor dilutive effect on existing shareholders.

Key Dates